This can lead not only to a shorter diagnostic process but also to the discovery of potential targets for personalized therapies via UPR-dependent molecular inhibitors, i.e., PERK-selected inhibitors for further investigations in RA patients. The gene discussed is EIF2AK3; the disease is rheumatoid arthritis.